My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
January 2014
Policy and Advocacy
HIVMA Welcomes HIV Policy Assessment Directive in Defense Bill
The HIV Medicine Association (HIVMA) joined numerous health and legal professionals in supporting a required report on the military’s HIV and hepatitis B policies that was included in the 2014 defense bill which Congress passed Dec. 20. 
 
The FY2014 National Defense Authorization Act includes two provisions that have the potential to eliminate discriminatory policies around HIV and hepatitis B by compelling the Department of Defense to medically justify current policies. This is a significant step toward reform of HIV criminalization laws.
 
The provisions require the Secretary of Defense to prepare a report for Congress concerning members of the Armed Forces who have HIV or hepatitis B. The report is to include a description of policies "addressing the enlistment or commissioning of individuals with these conditions” as well as “retention policies, deployment policies, discharge policies and disciplinary policies regarding individuals with these conditions." The defense act specifies that the report must include an assessment of whether these policies "reflect an evidence-based, medically accurate understanding" of how these conditions are contracted and transmitted. 
 
Michael Horberg, MD, FIDSA, an HIVMA Board member and former chair, hailed the defense bill’s HIV directive in a press release (PDF) issued by the Positive Justice Project, a network of individuals and agencies representing people with HIV. “The notion that people with HIV cannot enlist and serve in any aspect of the military, or that their health status warrants special 'safe sex' orders or punishments for consensual sex, seems rooted in a 1980’s understanding of HIV, and flies in the face of national efforts to get people with HIV tested and into treatment.”


< Previous Article | Next Article >

Post a comment

Your name:

Your comment:


Patient Care and Science
FDA Approves Simeprevir and Sofosbuvir for Chronic Hepatitis C
Policy and Advocacy
Congress Approves Partial Relief from Sequestration Funding Cuts
IDSA Supports Diagnostics Bill Moving through House of Representatives
IDSA and PIDS Submit Comments to FDA on Proposed Drug Shortage Rule
Congressional Briefing Highlights Barriers to Immunization for Older Adults
IDSA, SHEA, PIDS Call for Mandatory Immunization of Health Care Personnel
HIVMA Welcomes HIV Policy Assessment Directive in Defense Bill
President Obama Mentions Vaccines and Drug Resistance in State of the Union
Clinical Practice Management
New Resource Helps ID Specialists Prove Their Value
President Obama Signs Bill to Prevent Scheduled Medicare Cut
Science Speaks Blog
The Center for Global Health Policy Examines the Impact of Drug Prices on Vulnerable Populations, and Other Newsworthy Events
You and Your Colleagues
Renew Dues and Update Your Membership
Members on the Move
New Members
In Memoriam: Martin C. McHenry, MD, MS, FIDSA (1932-2013)
Education and Resources
Free Online Course on Antimicrobial Stewardship
Changes to ABIM MOC Now In Effect
Open Forum Infectious Diseases Now Accepting Submissions
Apply Now for the ID Research Careers Meeting
Top Story
From the President: New Website Provides Clinicians with Timely Advice on HCV
ADAPT Act Would Promote New Drug Development
Updated Guideline for Vaccination of Immunocompromised Host Now Available
IDSA Journal Club

IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'info@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.